Filling the need for trusted information on national health issues
Filling the need for trusted information on national health issues
Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.
With increased national attention towards prescription drug costs, this poll examines the public’s experiences with prescription medicine and their views on current policy proposals brought forth by congressional lawmakers and the Trump administration, including international reference pricing, transparency in drug advertisements, and negotiations with drug companies. The survey also dives into the attitudes and experiences of adults, 65 and older – a group that is more likely to report taking prescription medication and shopped for prescription drug coverage.
Prescription drug costs are a pressing concern for both consumers and policymakers. This analysis compares prescription drug spending and use in large private employer plans, Medicare Part D, and Medicaid, based primarily on claims data by payer, which does not account for rebates.
This policy brief includes background information on Medicaid and its drug benefit, provides examples of how states are using the cost containment mechanisms at their disposal and addresses issues surrounding beneficiary access to outpatient drugs.Policy Brief
Summarizes the coverage of outpatient prescription drugs by Medicaid. Many low-income seniors and other Medicaid recipients rely on this benefit as their only means of drug coverage. Information on the drug rebate program and utilization management procedures is included, as well as data on who uses the benefit, how much…
This report presents findings from a study of large private-sector employers conducted by researchers at Hewitt Associates and the Kaiser Family Foundation between July and September of 2002. The study is based on survey responses of 435 large private-sector firms (1,000+ employees) that currently offer retiree health benefits, and includes…
Health News Index May/June, 2001 The May/June 2001 edition of the Health News Index includes questions about major health stories covered in the news, including the Supreme Court ruling regarding the distribution of medical marijuana and the debate in Congress over a Patients Bill of Rights. This edition also includes…
Toplines: Seniors’ Early Experiences with the Medicare Prescription Drug BenefitThese toplines contain the detailed results from the April 2006 tracking poll on seniors’ early experiences with the new Medicare drug benefit.Toplines (.pdf)
This survey of state Medicaid pharmacy programs updates a survey conducted in 2000 and reports Medicaid prescription drug policies in effect in early 2003. It covers utilization management policies, payment and purchasing policies, utilization review policies, and policies for managed care enrollees and persons residing in institutions.Report (.pdf)
Topline findings from the May/June 2004 Kaiser Health Poll Report survey, including knowledge and opinions about the new Medicare prescription drug law.Survey Toplines (.pdf)
This paper, by Joy Pritts of the Health Policy Institute at Georgetown University, looks at issues related to drug plan marketing activities and privacy under the MMA.Issue Brief (.pdf)
, details the different types of private plan options available to people on Medicare. These include Medicare Advantage plans (such as Medicare HMOs, PPOs and private fee-for-service plans) and new stand-alone prescription drug plans.• In 2006, all Medicare beneficiaries have access to at least one type of private Medicare Advantage…
This Medicare Part D data spotlight focuses on the use of specialty tiers for high-cost and injectible drugs in Medicare Prescription Drug Plans in 2008. It finds that the number of plans with specialty tiers has nearly doubled since 2006. It also looks at the drugs assigned to specialty tiers,…